Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT01199523
First received: September 9, 2010
Last updated: July 1, 2013
Last verified: July 2013

September 9, 2010
July 1, 2013
May 2010
November 2010   (final data collection date for primary outcome measure)
QTcl evaluated through electrocardiogram analysis [ Time Frame: Day 1 to Day 11 in Treatment Period 1 and 2 ] [ Designated as safety issue: No ]
QTcI is a QT interval corrected for heart rate using individual-specific correction formula
Same as current
Complete list of historical versions of study NCT01199523 on ClinicalTrials.gov Archive Site
Pharmacodynamic assessment through electrocardiogram analysis [ Time Frame: Day 1 to Day 11 in Treatment Period 1 and 2 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females
A Phase 1, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Crossover Study to Evaluate the Effect of Repeat Oral Doses of Mirabegron on Cardiac Repolarization in Healthy Male and Female Adult Subjects

The objective of this study is to evaluate the effect of repeat oral dosing of mirabegron on ECG (electrocardiogram) measurements.

Each subject will be randomized and participate in two 10-day treatment periods during which once daily dosing of mirabegron and mirabegron/moxifloxacin placebo or moxifloxacin and moxifloxacin/mirabegron placebo will occur followed by a 1-day post-treatment period. Each treatment period will be separated by a washout period of at least 12 days from the last dose of study drug on Day 10 of Period 1 to Day -4 of Period 2.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Healthy Subjects
  • Drug: Placebo
    oral
  • Drug: mirabegron
    oral
    Other Name: YM178
  • Drug: moxifloxacin
    oral
    Other Name: Avelox
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: mirabegron high dose
    Intervention: Drug: mirabegron
  • Experimental: mirabegron medium dose
    Intervention: Drug: mirabegron
  • Experimental: mirabegron low dose
    Intervention: Drug: mirabegron
  • Active Comparator: moxifloxacin
    Intervention: Drug: moxifloxacin
Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, Mujais SK, Schaddelee MP, de Koning P, Kaibara A, Moy SS, Keirns JJ. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012 Dec;92(6):696-706. doi: 10.1038/clpt.2012.181. Epub 2012 Nov 14.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
352
November 2010
November 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject must weigh at least 45 kg and have a body mass index (BMI) between 20.0 and 28.5 kg/m2, inclusive
  • The female subject must be post-menopausal (defined as at least 2 years without menses) or surgically sterile (at least 1 month prior to screening). All women of child bearing potential will be required to use adequate contraception consisting of two forms of birth control (one of which must be a barrier method), must not be lactating, and must not be breastfeeding during the study period and for 30 days after final study drug administration. All women of childbearing potential must have a negative serum pregnancy test. Male subjects with female spouses/partners who are of childbearing potential must use contraception consisting of two forms of birth control (one of which must be a barrier method) during the study period and for 30 days after final study drug administration.
  • The subject must have negative test results for drugs of abuse and alcohol screens
  • The subject must have good venous access

Exclusion Criteria:

  • The subject is known to have hypersensitivity to mirabegron, or other adrenoreceptor agonists, or any of the constituents of the formulation used, or moxifloxacin or any member of the quinolone class of antimicrobial agents
  • The subject has a history of syncope, cardiac arrest, cardiac arrhythmia or torsade de pointes, structural heart disease, valvular abnormalities, or family history of long QT syndrome
  • The subject has experienced acute febrile illness within past 7 days
  • The subject has a history of tendonitis and/or liver function abnormality related to quinolone antibiotic treatment
  • The subject has a hyperthyroid disorder
  • The subject has a history or presence of psychiatric illness, or any medical condition or disorder that may compromise evaluation of drug effect, or is incapable of being compliant with the study procedures
  • The subject has donated or lost ≥ 450 mL blood within 56 days prior to study drug administration or has donated plasma within 7 days prior to study drug administration
  • The subject has received or is anticipated to receive a prescription drug within 14 days prior to Day -4 of Period 1 (within 30 days prior to Day -4 of Period 1 for any long acting treatments such as depot formulations). Subject has taken any over-the-counter (OTC) medications, including complementary and alternative medicines (except for hormonal contraceptives not including depot formulations, hormone replacement therapy and occasional use of acetaminophen of up to 2000 mg/day but not more than 4 days per week) within 14 days prior to Day -4 of Period 1
  • The subject has consumed alcohol, xanthine derivative-containing food/beverages (tea, chocolate), grapefruit juice, grapefruit-containing products or Seville oranges (e.g., bitter marmalade) within 48 hours before admission into the unit on Day -4 of Period 1
  • The subject has a recent history of alcohol or other substance abuse or any history of alcohol or substance dependence (with the exception of nicotine). The subject consumes more than 5 units of alcoholic beverages per week
  • The subject has used tobacco-containing products or nicotine-containing products within 6 months
  • The subject is currently participating in another clinical trial or is taking or has been taking an investigational drug 30 days or 10 half lives (whichever is longer), prior to first study drug administration
  • The subject is known to have hepatitis or human immunodeficiency virus (HIV)-1 and/or HIV-2, or is positive for hepatitis A antibody IgM, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody
  • The subject has any skin condition likely to interfere with electrocardiographic electrode placement or adhesion
  • The subject has a breast implant or a history of thoracic surgery likely to cause abnormality of the electrical conduction through thoracic tissues
  • The subject is unable to tolerate a controlled, quiet study conduct environment, including avoidance during specified times (e.g., during ECG monitoring days) of music, TV, movies, games and activities that may cause excitement, emotional tension or arousal
  • The subject is unwilling to comply with study rules, including attempting to void at restricted times (e.g., prior to ECG extraction windows), remaining quiet, awake, undistracted, motionless and supine during specified times, and avoiding vigorous exercise as directed
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01199523
178-CL-077
No
Astellas Pharma Inc
Astellas Pharma Inc
Not Provided
Study Director: Use Central Contact Astellas Pharma Global Development
Astellas Pharma Inc
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP